Newsroom

NAPLES, Fla., June 4, 2026— Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL) amyloidosis, a rare, progressive, debilitating, and often fatal condition.

Zamubafusp...

– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –

– CR rate now 95% (19 of 20 patients) –

– All CRs reached within 1 year of follow-up post-dosing –

– No relapses to-date observed for patients who have reached CR –

– All subsequently enrolled patients for...

PUBLISHED 29 May 2026 AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients...

Be sure to catch up on the latest happenings in our spring newsletter here!

Be sure to catch up on the latest happenings in our winter newsletter here!